Table 1. Summary of characteristics of identified in vivo study
Authors (Year)CountrySettingSample size (treatment/control)Mean age (SD)Inclusion criteriaTreatmentPrimaryoutcomeFindings
Gautret et al (2020)FranceHospitals in Marseille, Nice, Avignon and Briançon6 – AZT and HCQ14 – HCQ alone16 – controlTreatment groups: 51.2 (18.7)Control: 37.3 (24.0)
  • SARS-CoV-2 carriage in nasopharyngeal sample

  • Age>12 years (treatment groups only)

Six patients received 500 mg AZT on Day 1 then 250 mg daily for four days and200 mg HCQ three times a day for 10 days.14 patients received 200 mg HCQ three times a day for 10 days.Outcome of a nasopharyngeal swab on Day 6Virological cure:AZT and HCQ – 100%HCQ alone – 57.1%Controls – 12.5% p<0.001
  • AZT = azithromycin; HCQ = hydroxychloroquine.